Journal article 369 views 48 downloads
Organoids with a Type 1 Collagen Scaffold to Model Bacterial Cancer Therapy
,
Cleo Bonnet,
Alethea Tang,
Sev Peneva,
Non G. Williams ,
Sunil Dolwani,
Lee Parry ,
Paul Dyson
Cells, Volume: 14, Issue: 7, Start page: 524
Swansea University Authors:
Lydia Farrell , Alethea Tang, Sev Peneva, Paul Dyson
-
PDF | Version of Record
© 2025 by the authors. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license.
Download (11.33MB)
DOI (Published version): 10.3390/cells14070524
Abstract
Bacterial cancer therapy (BCT) is emerging as an important option for the treatment of solid tumours, with promising outcomes in preclinical trials. Further progress is hampered by an incomplete understanding of how oncotropic bacteria, such as attenuated strains of Salmonella enterica serovar Typhi...
| Published in: | Cells |
|---|---|
| ISSN: | 2073-4409 |
| Published: |
MDPI AG
2025
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa69267 |
| Abstract: |
Bacterial cancer therapy (BCT) is emerging as an important option for the treatment of solid tumours, with promising outcomes in preclinical trials. Further progress is hampered by an incomplete understanding of how oncotropic bacteria, such as attenuated strains of Salmonella enterica serovar Typhimurium, colonise tumours and the responses of both the bacteria and tumour cells to this colonisation. To model this, we developed organoids that are permissive for bacterial colonisation, replacing the conventional commercially available extracellular matrix (e.g., Matrigel) with a type I collagen matrix scaffold. A comparison of the two extracellular matrices indicated that type 1 collagen permitted an initial infection efficiency more than 5-times greater than with Matrigel. In addition, subsequent growth within type 1 collagen expanded bacterial cell numbers by over 10-fold within 4 days of infection. These organoids allow for the visualisation of bacterial chemoattraction, cell invasion and subsequent population of the interior lumen, and will permit the future optimisation of BCT. In addition, by establishing patient-derived organoids, we demonstrate a platform for developing future personalised treatments exploiting BCT. |
|---|---|
| Keywords: |
bacterial cancer therapy; organoid; Salmonella enterica serovar Typhimurium; personalised medicine; type 1 collagen |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Funders: |
This research was funded by grants from Cancer Research UK (reference: C23498/A27517) to L.P., S.D. and P.D. and the Research Wales Innovation Fund (reference R3-EEF43) to P.D. |
| Issue: |
7 |
| Start Page: |
524 |